Decentralised Clinical Trials: Balance Innovation and Integrity

Decentralised clinical trials (DCTs) are transforming drug development by reducing patient burden and expanding access. Yet sponsors must balance innovation with data integrity and regulatory compliance to ensure DCT design success.

Image

Why Decentralisation Matters for Running Successful Clinical Trials

Traditional site-based trials often struggle with patient recruitment, retention, and geographic limitations.

Decentralised models (using telemedicine, home health visits, and digital monitoring) expand access to diverse populations and reduce logistical barriers.

For patients, this means greater convenience.

For sponsors, it means faster enrolment and broader datasets.

Core Features of Decentralised Clinical Trials

The core features of DCTs are:

• Remote Recruitment: Digital platforms identify and enroll patients outside traditional sites.
• Telemedicine Visits: Virtual consultations reduce travel and improve retention.
• Home Health Services: Nurses and mobile labs bring trial procedures directly to patients.
• Digital Monitoring: Wearables and apps provide continuous data streams.

Benefits of DCTs for Sponsors and Patients

Decentralised clinical trials improve recruitment diversity, reduce dropout rates, and shorten drug clinical trial timelines. Patients benefit from reduced travel and more flexible participation.

Sponsors gain efficiency and richer datasets, particularly for studies of chronic conditions and rare diseases.

Challenges and Risks for Designing DCTs

There are many risks and challenges associated with DCT design, including:

• Data Integrity: Remote data capture must meet regulatory standards.
• Technology Access: Not all patients have reliable internet or devices.
• Regulatory Variation: Agencies differ in their acceptance of decentralised evidence.
• Operational Complexity: Coordinating home health, logistics, and digital platforms requires robust planning.

View interview Could Biological Ageing Be the Next Big Shift in Drug Discovery?

Could Biological Ageing Be the Next Big Shift in Drug Discovery?

“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."

Image

Strategic Implications for R&D Leaders

Decentralisation is not a replacement for traditional trials; rather, it's a complementary model.

Sponsors must integrate decentralised elements where they add value, while ensuring compliance and data quality.

Early engagement with regulators is essential to align protocols with evolving standards.

Conclusion: DCT Trials Are Reshaping Clinical Trials

Decentralised clinical trials are reshaping participation and evidence generation, but success depends on balancing innovation with integrity.

Pharmatica provides the strategic intelligence that connects decentralised trial models to real-world R&D decisions, enabling leaders to recruit, monitor, and deliver clinical strategy with clarity.

Pharmatica: Insight. Connection. Impact.